Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
09:11am, Monday, 04'th Aug 2025
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $1.24 per share a year ago.
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
07:00am, Monday, 04'th Aug 2025
Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY ® 2Q 2025 net product sales of $119.6 million, representing growth of 84%
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Monday, 28'th Jul 2025
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy
01:46pm, Friday, 25'th Jul 2025
Axsome's valuation is driven by its promising pipeline, with Auvelity as a proven commercial success and Symbravo and AXS-12 showing solid potential. Recent setbacks include the FDA's refusal to file
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
05:51am, Thursday, 24'th Jul 2025
Should you invest in stocks right now? Some might be hesitant to do so because of the volatility broader equities have faced this year.
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
07:30am, Monday, 21'st Jul 2025
Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
07:00am, Wednesday, 09'th Jul 2025
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
07:00am, Friday, 20'th Jun 2025
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
07:00am, Wednesday, 11'th Jun 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
2 Soaring Stocks Wth More Upside Potential
03:19am, Thursday, 05'th Jun 2025
Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after ma
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
12:37pm, Wednesday, 04'th Jun 2025
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Thursday, 29'th May 2025
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
07:00am, Tuesday, 27'th May 2025
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,
3 High-Flying Stocks That Could Soar Even More
06:40am, Saturday, 24'th May 2025
Many investors love the "big mo." That's short for "big momentum.
